Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZGN-433 · 2 trials · 1 indication
Measures of the safety and tolerability of ZGN-433 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, heart rhythm, and laboratory tests.
| Arm | Type | Description |
|---|---|---|
| Normal Saline | PLACEBO_COMPARATOR | - |
| ZGN-433 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZGN-433 | DRUG | Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated. |
| Normal Saline | DRUG | Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated. |
Inclusion Criteria: * Obese but otherwise healthy females * Non-childbearing potential (surgically sterile, post-menopausal, or receiving implanted or injectable contraceptive for at least 3 months) * BMI ≥ 30 and ≤ 50 kg/m2 * Stable body weight during the past month Exclusion Criteria: * Use of ...
Top 20 of 32 competitors
ZGN-433 is an investigational small molecule being developed for the treatment of obesity. It is a metabolic therapeutic that has been studied in Phase 1 clinical trials in obese female volunteers. The drug is not yet approved and remains in clinical development.
ZGN-433 is being developed by Larimar Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LRMR. The company has conducted Phase 1 clinical trials of ZGN-433 in Australia.
ZGN-433 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving obese female volunteers. The drug is investigational and has not been approved by regulatory authorities.
ZGN-433 has completed two Phase 1 clinical trials. The first, NCT01028261, studied multiple doses in 31 obese female volunteers. The second, NCT01372761, studied intravenous doses in 25 obese female volunteers. Both trials were conducted in Australia.
ZGN-433 is the primary name for this investigational drug. No alternative names have been reported in the clinical trial records. It is a small molecule therapeutic being developed for obesity.